IP Verse

Methods Of Using Sustained Release Aminopyridine Compositions - EP2377536

The patent EP2377536 was granted to Acorda Therapeutics on Aug 17, 2022. The application was originally filed on Apr 11, 2005 under application number EP11160247A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2377536

ACORDA THERAPEUTICS
Application Number
EP11160247A
Filing Date
Apr 11, 2005
Status
Patent Maintained As Amended
Jul 15, 2022
Grant Date
Aug 17, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

NEURAXPHARM ARZNEIMITTELDec 6, 2013KONIGERADMISSIBLE
SYNTHONDec 6, 2013PRINSADMISSIBLE
ACTAVIS GROUP PTC EHFDec 5, 2013ELKINGTON AND FIFEADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20040010828-
DESCRIPTIONUS20040560894-
DESCRIPTIONUS2004008101
DESCRIPTIONUS5952357
SEARCHIE82916

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BLIGHT, A.R., "Axonal physiology of chronic spinal cord injury in the cat: intracellular recording in vitro", NEUROSCIENCE, (1983), vol. 10, pages 1471 - 1486-
DESCRIPTION- BLIGHT, A.R., "Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury", BRAIN RES. BULL., (1989), vol. 22, pages 47 - 52-
DESCRIPTION- BLIGHT, A.R., GRUNER, J.A., "Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal- injured cats", J. NEUROL. SCI., (1987), vol. 82, pages 145 - 159-
DESCRIPTION- BLIGHT, A.R., "The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial", J. NEUROTRAUMA, (1991), vol. 8, pages 103 - 119-
DESCRIPTION- HAYES ET AL., "Effects of intravenous 4-aminopyridine on neurological function in chronic spinal cord injured patients: preliminary observations", PROC. IBRO WORLD CONF. NEUROSCI., (1991), page 345-
DESCRIPTION- KEITH C. HAYES, PATRICK J. POTTER, ROBERT R. HANSEBOUT, JOANNE M. BUGARESTI, JANE T. C. HSIEH, SERA NICOSIA, MITCHELL A. KATZ, AND, CLINICAL NEUROPHARMACOLOGY, (2003), vol. 26, no. 4, pages 185 - 192-
DESCRIPTION- S.M. BARGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19-
DESCRIPTION- T. HIGUCHI, V. STELLA, "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14-
EXAMINATION- GOODMAN ANDREW D ET AL, "Placebo-controlled double-blinded dose ranging study of fampridine-SR in multiple sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (20030311), vol. 60, no. 5 Supplement 1, ISSN 0028-3878, page A167, XP009154279-
OPPOSITION- Goodman et al, S21.001, fromA167 NEUROLOGY 60 March 2003 (Suppl 1)-
OPPOSITION- Goodman et a!., Poster presented during the 7th Annual Meeting on the American Committee for the Treatment and Research in Multiple Sclerosis and the 18th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis, September 18-21,2002-
OPPOSITION- SEC Form S-1, Acorda Therapeutics,Inc., September 26 2003, published 30 September 2003-
OPPOSITION- DAVIS et al., "Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis", Ann Neurol., (19900200), vol. 27, no. 2, pages 186 - 192, XP055260954
SEARCH- BEVER C T JR ET AL, "The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (19940601), vol. 44, no. 6, ISSN 0028-3878, pages 1054 - 1059, XP009115521 [X] 1-22 * see "Treatment" *-
SEARCH- SCHWID S R ET AL, "Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (19970401), vol. 48, no. 4, ISSN 0028-3878, pages 817 - 821, XP009115522 [X] 1-22 * see "Procedure". *-
SEARCH- VAN DIEMEN H A M ET AL, "THE EFFECT OF 4 AMINOPYRIDINE ON CLINICAL SIGNS IN MULTIPLE SCLEROSIS A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND CROSS-OVER STUDY", ANNALS OF NEUROLOGY, (1992), vol. 32, no. 2, ISSN 0364-5134, pages 123 - 130, XP002524401 [X] 1-22 * abstract *
SEARCH- BEVER C T, "THE CURRENT STATUS OF STUDIES OF AMINOPYRIDINES IN PATIENTS WITH MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, BOSTON, US, (19940101), vol. 36, ISSN 0364-5134, pages S118 - S121, XP000653261 [X] 1-22 * table 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents